Nystatin

Polyene Antifungal — ALIMENTARY TRACT AND METABOLISM

Key facts

Nystatin is an ofp drug in the Polyene Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 1964. Recorded indications include Candidal vulvovaginitis, Candidiasis of mouth, Candidiasis of skin and Gastrointestinal candidiasis.

• Approval status: ofp (first approved 1964 by the FDA).
• Drug class: Polyene Antifungal.
• Indications: Candidal vulvovaginitis, Candidiasis of mouth, Candidiasis of skin, Gastrointestinal candidiasis and Mucocutaneous candidiasis.
• ATC code: A07AA02 (Antibiotics).
• Molecular formula: C47H75NO17; molecular weight 926.11 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Candidal vulvovaginitis
• Candidiasis of mouth
• Candidiasis of skin
• Gastrointestinal candidiasis
• Mucocutaneous candidiasis

Off-label uses (1)

• Diaper rash

Contraindications (3)

• Adrenal cortical hypofunction
• Atrophoderma
• Telangiectasia disorder

Mechanism & targets

• Established pharmacologic class: Polyene Antifungal

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1964-07-08	FDA	—	DELCOR ASSET CORP

ATC classification

ATC code	Therapeutic hierarchy
A07AA02	ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
D01AA01	DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Antibiotics
G01AA01	GENITO URINARY SYSTEM AND SEX HORMONES › GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS › ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS › Antibiotics
G01AA51	GENITO URINARY SYSTEM AND SEX HORMONES › GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS › ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS › Antibiotics
J01RA19	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › COMBINATIONS OF ANTIBACTERIALS › Combinations of antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Candida infection	393.7
Schizophrenia	390.2
Febrile neutropenia	375.3
Hypomania	348.0
Jaundice cholestatic	303.9
Oral candidiasis	248.6
Pneumonia	228.1
Cholelithiasis	221.7
Nasal polyps	220.6
Total lung capacity increased	205.8
Hand deformity	190.2
Asthma-chronic obstructive pulmonary disease overlap syndrome	187.6

Chemical structure

• Molecular formula: C₄₇H₇₅NO₁₇
• Molecular weight: 926.11 g/mol
• CAS number: —
• InChIKey: VQOXZBDYSJBXMA-NQTDYLQESA-N
• PubChem CID: 6433272

C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nystatin used for?

DrugCentral lists the following indications for Nystatin: Candidal vulvovaginitis, Candidiasis of mouth, Candidiasis of skin, Gastrointestinal candidiasis and Mucocutaneous candidiasis.

When was Nystatin first approved?

Nystatin was first approved by the FDA in 1964.

What drug class does Nystatin belong to?

Nystatin is in the Polyene Antifungal class.

What is the chemical formula of Nystatin?

Nystatin has the molecular formula C47H75NO17 and a molecular weight of 926.11 g/mol.

Sources

• DrugCentral drug card 1977 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5465559 — compound record and bioactivity
• PubChem CID 6433272 — chemical identifiers
• DrugBank DB00646 — drug record
• FDA UNII BDF1O1C72E — substance identity
• DailyMed: FDA labels for Nystatin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.